Previous Ebola outbreaks have aided Uganda's response to COVID-19
Health workers in Uganda have been fighting off Ebola outbreaks for 20 years. This not only has contributed to the count...
We are optimistic about a new tool in the fight against Ebola. The phase III trials on efficacy of the VSV-ZEBOV vaccine have yielded an impressive result in a relatively short time - 100% effectiveness in those receiving the vaccine.Scientists still need to figure out how long its protection lasts, and how effective it will be among the general population and with different strains of the virus. But without a doubt, this is an important tool for the protection of health and community workers and possibly the wider community. This will certainly help in the on-going efforts to achieve the target of zero new Ebola cases.
View SourceThis notice has been removed
The content is no longer available
We are optimistic about a new tool in the fight against Ebola. The phase III trials on efficacy of the VSV-ZEBOV vaccine have yielded an impressive result in a relatively short time - 100% effectiveness in those receiving the vaccine.Scientists still need to figure out how long its protection lasts, and how effective it will be among the general population and with different strains of the virus. But without a doubt, this is an important tool for the protection of health and community workers and possibly the wider community. This will certainly help in the on-going efforts to achieve the target of zero new Ebola cases.
No results found
Try a different search term
Something went wrong
No notices yet
No notices match these filters
Couldn't load notices
You're all caught up 🎉
Sign in to continue to Global Noticeboard
Enter your email to receive a reset link
Create a new password for your account
You are marking this Notice are inappropriate, and you belive it infringes on the Global Noticeboard Community Guidelines (link). Is this so?
Create 3 Noticeboards to earn this Silver level Community Champion Badge.
View all badges that you can earnPlease tell us why you are reporting this content.
Discussion (0)
No comments yet